BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection
June 29, 2021 13:58 ET | BioAegis Therapeutics
NORTH BRUNSWICK, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
logo.png
Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
June 24, 2021 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Study did not meet primary endpoint of Total Improvement Score (TIS) at Week 28Additional findings included nominally significant improvements in TIS (p = 0.0302) and CDASI (p = 0.0166) depending on...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
Study Identifies New Role of BioAegis’ ‘Inflammation Regulator’ Gelsolin Relevant for a Range of Inflammatory Diseases
April 08, 2021 18:58 ET | BioAegis Therapeutics
Gelsolin mitigates vascular damage by preventing release of IL-1β microparticles after trauma of high pressure and decompression.  Gelsolin is non-immunosuppressive unlike current treatments to quell...
Silencil Reviews: Negative Side Effects or Real Tinnitus Aid
April 04, 2021 06:00 ET | Marketing By Kevin
Chicago, IL, April 04, 2021 (GLOBE NEWSWIRE) -- Silencil is a daily supplement for tinnitus to alleviate the ringing in the ears that is caused by inflammation in the brain. The formula, found...
180_LS_logo.png
180 Life Sciences Corp. (NASDAQ: ATNF) in Hot Pursuit of New Anti-Inflammatory Blockbusters
March 25, 2021 08:30 ET | 180 Life Sciences Corp.
NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — 180 Life Sciences Corp. (NASDAQ: ATNF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Completes Recruitment for Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment
March 15, 2021 11:12 ET | BioAegis Therapeutics
MORRISTOWN, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based...
thumbnail_Pan-Biome-logo.png
Pan-Biome Pharmaceuticals, Inc reports positive results in preclinical trial of Inflammatory Bowel Disease: oral drug shows strong effect in modulating the gut microbiome
February 24, 2021 10:00 ET | Pan-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Pan-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on chronic inflammatory and autoimmune...
Equillium_Square_Logo.png
Equillium Announces the Appointment of Katherine Xu to the Board of Directors
February 09, 2021 08:00 ET | Equillium
LA JOLLA, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
NIH and Other Independent Studies Confirm Low Levels of BioAegis’ ‘Inflammation Regulator Protein,’ Gelsolin, Associated with COVID-19 Severity
February 02, 2021 14:05 ET | BioAegis Therapeutics
MORRISTOWN, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
New book provides a simple solution to conquer inflammation, the underlying cause of the majority of the disease today
January 18, 2021 18:00 ET | Balboa Press
SAN DIEGO, Jan. 18, 2021 (GLOBE NEWSWIRE) -- As a cancer survivor who has experienced the devastating effects of cancer, Dr. Bruce Howe made it his mission to research the subject of inflammation...